Grundläggande statistik
| CIK | 1171298 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Solta Medical Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 14, 2014 |
SLTM / Solta Medical Inc / MERITECH CAPITAL PARTNERS II LP - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 4) * Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2013 (Date of Event Which Require |
|
| February 14, 2014 |
SLTM / Solta Medical Inc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2014 |
SLTM / Solta Medical Inc / Longitude Capital Partners, LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 v368111sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 par value (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) |
|
| February 7, 2014 |
SLTM / Solta Medical Inc / DELPHI VENTURES VII L P - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Solta Medical, Inc. (f/k/a Thermage, Inc.) (Name of Issuer) Common Stock (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2013 (Date of Event Which Req |
|
| February 3, 2014 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33123 SOLTA MEDICAL, INC. (Exact name of registrant as specifie |
|
| January 24, 2014 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SOLTA MEDICAL, INC. EX-3.1 2 d660080dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SOLTA MEDICAL, INC. FIRST: The name of the Corporation is Solta Medical Inc., (hereinafter the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registe |
|
| January 24, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2014 Solta Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Comm |
|
| January 24, 2014 |
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES ACQUISITION OF SOLTA MEDICAL, INC. Exhibit 99.2 International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES ACQUISITION OF SOLTA MEDICAL, INC. Laval, Quebec — January 23, 2014 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“V |
|
| January 24, 2014 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF SOLTA MEDICAL, INC. A Delaware Corporation Effective January 23, 2014 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 2 Section 1. Place of Meetings 2 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 3 Section 5. Adjournments 3 Sect |
|
| January 23, 2014 |
FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
S-8 POS 1 d660097ds8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. 333-138958 Registration No. 333-141885 Registration No. 333-149739 Registration No. 333-158333 Registration No. 333-165619 Registration No. 333-172881 Registration No. 333-180100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AME |
|
| January 23, 2014 |
FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) SOLTA MEDICAL, INC. (Name of Subject Company (Issuer)) Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharma |
|
| January 23, 2014 |
S-8 POS 1 d660097ds8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. 333-138958 Registration No. 333-141885 Registration No. 333-149739 Registration No. 333-158333 Registration No. 333-165619 Registration No. 333-172881 Registration No. 333-180100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AME |
|
| January 23, 2014 |
As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES TENDER OFFER FOR SOLTA MEDICAL, INC. EX-99.(a)(5)(D) Exhibit (a)(5)(D) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES TENDER OFFER FOR SOLTA MEDICAL, INC. Laval, Quebec — January 23, 2014 — Valeant Pharmaceuticals International, Inc. (NYSE |
|
| January 23, 2014 |
POS AM As Filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
FORM S-8 POS As filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
POS AM As Filed with the Securities and Exchange Commission on January 23, 2014 Registration No. |
|
| January 23, 2014 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) SOLTA MEDICAL, INC. (Name of Subject Company) SOLTA MEDICAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 83438K103 (CU |
|
| January 15, 2014 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLTA MEDICAL, INC. (Name of Subject Company) SOLTA MEDICAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 83438K103 (CU |
|
| January 15, 2014 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) SOLTA MEDICAL, INC. (Name of Subject Company (Issuer)) Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharma |
|
| January 15, 2014 |
EX-99.(a)(5)(C) Exhibit (a)(5)(C) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF SOLTA MEDICAL, INC. Laval, Quebec — January 15, 2014 — Valeant Pha |
|
| January 13, 2014 |
Form SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) SOLTA MEDICAL, INC. (Name of Subject Company (Issuer)) Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant P |
|
| January 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLTA MEDICAL, INC. (Name of Subject Company) SOLTA MEDICAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 83438K103 (CUSIP Number |
|
| December 23, 2013 |
Request for Taxpayer Identification Number and Certification EX-99.(a)(1)(F) Exhibit (a)(1)(F) Form W-9 (Rev. August 2013) Department of the Treasury Internal Revenue Service Request for Taxpayer Identification Number and Certification Give Form to the requester. Do not send to the IRS. Print or type See Specific Instructions on page 2. Name (as shown on your income tax return) Business name/disregarded entity name, if different from above Check appropriate |
|
| December 23, 2013 |
Exhibit (d)(7) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. |
|
| December 23, 2013 |
EX-99.(d)(12) Exhibit (d)(12) CONFIDENTIALITY AGREEMENT This CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of July 7, 2012 between Solta Medical, Inc., a Delaware corporation (“SMI”) and Valeant Pharmaceuticals International, Inc., a Canadian corporation (“VPII” and with SMI referred to collectively as the “Parties” and individually as a “Party”). In order to facilitate the cons |
|
| December 23, 2013 |
EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Solta Medical, Inc. at $2.92 Per Share, Net in Cash, by Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDN |
|
| December 23, 2013 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of Solta Medical, Inc. at $2.92 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated December 23, 2013 by Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internationa |
|
| December 23, 2013 |
Exhibit (a)(5)(B) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 23, 2013 |
EX-99.(D)(2) 9 d645423dex99d2.htm EX-99.(D)(2) Exhibit (d)(2) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and HAROLD L. COVERT TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Sub |
|
| December 23, 2013 |
EX-99.(D)(9) 16 d645423dex99d9.htm EX-99.(D)(9) Exhibit (d)(9) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and JEFF NARDOCI TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subjec |
|
| December 23, 2013 |
EX-99.(D)(10) 17 d645423dex99d10.htm EX-99.(D)(10) Exhibit (d)(10) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and MARK M. SIECZKAREK TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership |
|
| December 23, 2013 |
EX-99.(A)(1)(D) 5 d645423dex99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) Letter to Brokers and Dealers with Respect to Offer to Purchase All Outstanding Shares of Common Stock of Solta Medical, Inc. at $2.92 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated December 23, 2013 by Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned |
|
| December 23, 2013 |
EX-99.(D)(11) 18 d645423dex99d11.htm EX-99.(D)(11) Exhibit (d)(11) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and ERIC STANG TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subj |
|
| December 23, 2013 |
Exhibit (d)(8) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. |
|
| December 23, 2013 |
EX-99.(D)(5) 12 d645423dex99d5.htm EX-99.(D)(5) Exhibit (d)(5) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and LINDA GRAEBNER TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subj |
|
| December 23, 2013 |
EX-99.(D)(13) 20 d645423dex99d13.htm EX-99.(D)(13) Exhibit (d)(13) October 31, 2013 CONFIDENTIAL Valeant Pharmaceuticals International, Inc. 4787 Levy Street Montreal, Quebec H4R 2P9 Attention: Robert R. Chai-Onn Re: Extension of Confidentiality Agreement Dear Mr. Chai-Onn: Reference is made to that certain Confidentiality Agreement (the “Agreement”) entered into as of July 7, 2012 (the “Effective |
|
| December 23, 2013 |
EX-99.(D)(4) 11 d645423dex99d4.htm EX-99.(D)(4) Exhibit (d)(4) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and JOHN GLENN TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subject |
|
| December 23, 2013 |
EX-99.(D)(6) 13 d645423dex99d6.htm EX-99.(D)(6) Exhibit (d)(6) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and DAVID HOLTHE TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subjec |
|
| December 23, 2013 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 SOLTA MEDICAL, INC. (Name of Subject Company (Issuer)) Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internatio |
|
| December 23, 2013 |
EX-99.(A)(1)(E) 6 d645423dex99a1e.htm EX-99.(A)(1)(E) Exhibit (a)(1)(E) Letter to Clients with Respect to Offer to Purchase All Outstanding Shares of Common Stock of Solta Medical, Inc. at $2.92 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated December 23, 2013 by Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary o |
|
| December 23, 2013 |
EX-99.(d)(3) Exhibit (d)(3) TENDER AGREEMENT Dated as of December 15, 2013 among VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP. and H. DANIEL FERRARI TABLE OF CONTENTS ARTICLE I AGREEMENT TO TENDER Section 1.1 Agreement to Tender 1 ARTICLE II REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDER Section 2.1 Authority 2 Section 2.2 Ownership of Subject Securities 2 Section 2.3 Con |
|
| December 23, 2013 |
Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 23, 2013 |
EX-99.(A)(1)(G) 2 d648680dex99a1g.htm EX-99.(A)(1)(G) Exhibit (a)(1)(G) December 23, 2013 Dear Solta Medical Stockholders: We are pleased to report that Solta Medical, Inc. (the “Company”) has entered into an Agreement and Plan of Merger, dated as of December 15, 2013 (the “Merger Agreement”), with Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Sapphire Subsidiary Corp., |
|
| December 23, 2013 |
Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION Letter of Transmittal To Tender Shares of Common Stock of Solta Medical, Inc. |
|
| December 17, 2013 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG VALEANT PHARMACEUTICALS INTERNATIONAL, SAPPHIRE SUBSIDIARY CORP., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. AND SOLTA MEDICAL, INC. DATED AS OF DECEMBER 15, 2013 TABLE OF CONTENTS PAGE ARTICLE I THE OFFER Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 Directors 5 ARTICLE II THE MERGER Section 2.1 The Merge |
|
| December 17, 2013 |
EX-99.A.5.A Exhibit (a)(5)(A) International Headquarters 25881 Industrial Blvd. 2150 St. Elzéar Blvd. West Hayward, CA., 94545 Laval, Quebec H7L 4A8 Main: 510.782.2286 Phone: 514.744.6792 FAX: 510.782.2287 Fax: 514.744.6272 Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash 12/16/2013 Combination Creates a Global Leader in Aesthetics Transaction Values Solta at App |
|
| December 17, 2013 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 SOLTA MEDICAL, INC. (Name of Subject Company (Issuer)) Sapphire Subsidiary Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internatio |
|
| December 17, 2013 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SOLTA MEDICAL, INC. (Name of Subject Company) SOLTA MEDICAL, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 83438K-103 (CUSIP Number of Class |
|
| December 17, 2013 |
EX-99.1 Exhibit 99.1 International Headquarters 25881 Industrial Blvd. 2150 St. Elzéar Blvd. West Hayward, CA., 94545 Laval, Quebec H7L 4A8 Main: 510.782.2286 Phone: 514.744.6792 FAX: 510.782.2287 Fax: 514.744.6272 Contact Information: Solta Medical, Inc. Valeant Pharmaceuticals International, Inc. Investors: Investors and Media: Jenifer Kirtland Laurie W. Little 415-568-9349 949-461-6002 jkirtlan |
|
| December 17, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2013 (December 15, 2013) Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incor |
|
| December 10, 2013 |
Correspondence December 10, 2013 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Attention: Kevin L. Vaughn Tara Harkins Eric Atallah Re: Solta Medical, Inc. Form 10-K for Fiscal Year Ended December 31, 2012 Filed March 6, 2013 File No. 001-33123 Ladies and Gentlemen: Solta Medical, Inc. (the “Company”) provides this |
|
| December 10, 2013 |
8-K 1 d640308d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of in |
|
| December 3, 2013 |
8-K 1 d634746d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 26, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of |
|
| November 20, 2013 |
8-K 1 d629969d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2013 SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of inco |
|
| November 15, 2013 |
FORBEARANCE AND FIRST AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.2 FORBEARANCE AND FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FORBEARANCE AND FIRST AMENDMENT to Amended and Restated Loan and Security Agreement (this “Agreement”) is entered into as of November 8, 2013, by and between Silicon Valley Bank (“Bank”) and Solta Medical, Inc., a Delaware corporation (“Borrower”). RECITALS A. Bank and Borrower have entered into t |
|
| November 15, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 S |
|
| November 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 1-33123 CUSIP Number: 83438K-103 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 1 |
|
| November 12, 2013 |
EX-99.2 Exhibit 99.2 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its aff |
|
| November 12, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2013 |
EX-99.1 Exhibit 99.1 Solta Medical Reports Third Quarter 2013 Results and Actions Implemented to Improve Shareholder Returns Restructuring Plan Projected to Reduce Annual Expenses by $12 Million Expects to Generate More Than $8 Million in Cash Flow from Operations in 2014 Engages Piper Jaffray & Co. as Financial Advisor Expects to Complete New Debt Financing Agreement HAYWARD, Calif., November 11, |
|
| September 5, 2013 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 30, 2013 between SILICON VALLEY BANK, a California corporation (“Bank”), and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) amends and restates, in its entirety, that certain Loan and Security Agreement between Borrower and Bank dated a |
|
| September 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission File |
|
| August 23, 2013 |
8-K 1 d539682d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of i |
|
| August 7, 2013 |
SOLTA MEDICAL, INC. AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE AGREEMENT EX-10.3 Exhibit 10.3 SOLTA MEDICAL, INC. AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between JOHN “JACK” GLENN (“Executive”) and Solta Medical, Inc. (the “Company”), effective as of April 1, 2013 (the “Effective Date”). RECITALS 1. It is expected that the Company fro |
|
| August 7, 2013 |
TENTH AMENDMENT LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 TENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS TENTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of August 5, 2013 by and between SILICON VALLEY BANK (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into that ce |
|
| August 7, 2013 |
CHANGE OF CONTROL AND SEVERANCE AGREEMENT EX-10.2 Exhibit 10.2 CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between STEPHEN J. FANNING (“Executive”) and Solta Medical, Inc. (the “Company”), effective as of April 1, 2013 (the “Effective Date”). RECITALS 1. It is expected that the Company from time to time will consider the possibility of an acquisitio |
|
| August 7, 2013 |
SOLTA MEDICAL, INC. AMENDED AND RESTATED FORM OF CHANGE OF CONTROL AND SEVERANCE AGREEMENT EX-10.4 Exhibit 10.4 SOLTA MEDICAL, INC. AMENDED AND RESTATED FORM OF CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between (“Executive”) and Solta Medical, Inc. (the “Company”), effective as of April 1, 2013 (the “Effective Date”). RECITALS 1. It is expected that the Company from time to |
|
| August 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 SOLTA |
|
| August 6, 2013 |
EX-99.1 Exhibit 99.1 Solta Medical Reports Second Quarter 2013 Results Mark Sieczkarek Appointed Interim President and Chief Executive Officer HAYWARD, Calif., August 6, 2013 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the second quarter ended June 30, 2013. In addition, the Company announced the resignation of Stephen J. Fann |
|
| August 6, 2013 |
8-K 1 d579519d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of in |
|
| June 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| May 24, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 24, 2013 |
Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. EX-99.1 Exhibit 99.1 Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. Hayward, Calif., May 24, 2013—-Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today reported Dr. Edward W. Knowlton has resigned as a member of the Company’s Board of Directors effective immediately. Dr. Knowlton is the founder of Thermage, the predecessor company to Solt |
|
| May 24, 2013 |
8-K 1 d544617d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorp |
|
| May 16, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d539713ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| May 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Solta Medical, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 83438K103 (CUSIP Number) February 26, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 3, 2013 |
SECOND AMENDMENT TO LEASE (Extension of Term) EX-10.5 4 d514518dex105.htm EX-10.5 Exhibit 10.5 SECOND AMENDMENT TO LEASE (Extension of Term) THIS SECOND AMENDMENT TO LEASE (“Second Amendment”) is made and entered into by and between MCCASLIN PLAZA LLC, a Colorado limited liability company (“Landlord”), and SOUND SURGICAL TECHNOLOGIES LLC, a Colorado limited liability company (“Tenant”), and amends that certain Lease dated May 30, 2003 (“Origi |
|
| May 3, 2013 |
THIRD AMENDMENT TO LEASE (Extension of Term; Expansion of Premises) EX-10.6 Exhibit 10.6 THIRD AMENDMENT TO LEASE (Extension of Term; Expansion of Premises) THIS THIRD AMENDMENT TO LEASE (“Third Amendment”) is made and entered into by and between MCCASLIN PLAZA LLC, a Colorado limited liability company (“Landlord”), and SOUND SURGICAL TECHNOLOGIES LLC, a Colorado limited liability company (“Tenant”), and amends that certain Lease dated May 30, 2003 (“Original Leas |
|
| May 3, 2013 |
Solta Medical, Inc. 13,300,152 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| May 3, 2013 |
EX-10.4 3 d514518dex104.htm EX-10.4 Exhibit 10.4 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of this day of , 2006, by and between MCCASLIN PLAZA LLC, a Colorado limited liability company (“Landlord”), and SOUND SURGICAL TECHNOLOGIES LLC, a Colorado limited liability company (“Tenant”). RECITALS: WHEREAS, Landlord and Tenant are parties to that certai |
|
| May 3, 2013 |
LEASE BETWEEN Sound Surgical Technologies LLC McCaslin Plaza, LLC EX-10.3 Exhibit 10.3 LEASE BETWEEN Sound Surgical Technologies LLC AND McCaslin Plaza, LLC Current as of June 20, 2003 TABLE OF CONTENTS SECTION 1 PURPOSE 1 SECTION 2 TERM 2 SECTION 3 COMPLETION OF PREMISES 2 SECTION 4 RENT 2 SECTION 5 TAXES AND OPERATING COST ADJUSTMENT FORMULA 4 SECTION 6 HOLDING OVER 8 SECTION 7 BUILDING SERVICES 8 SECTION 8 CONDITION OF PREMISES 9 SECTION 9 USE OF LEASED PREMI |
|
| May 1, 2013 |
Solta Medical Reports First Quarter 2013 Results Exhibit 99.1 Solta Medical Reports First Quarter 2013 Results HAYWARD, Calif., May 1, 2013 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2013. Revenue for the first quarter was $34.5 million, an increase of $2.1 million, or 6%, as compared to the first quarter of 2012. The year-over-year revenue |
|
| May 1, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 29, 2013 |
S-3/A 1 d513868ds3a.htm S-3/A Table of Contents As filed with the Securities and Exchange Commission on April 29, 2013 Registration No. 333-187657 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 68-0373593 (Sta |
|
| April 22, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 17, 2013 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.3 3 exhibit3.htm EXHIBIT 3 Exhibit 3 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing |
|
| April 17, 2013 |
SLTM / Solta Medical Inc / Inlign CP III, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83438K103 (CUSIP Number) Mary J. Mullany Ballard Spahr LLP 1735 Market Street 51st floor Philadelphia, Pennsylvania 19103 (215) 665-8500 (Name, Address and Telephon |
|
| April 17, 2013 |
EX-99.2 2 exhibit2.htm EXHIBIT 2 Exhibit 2 January 23, 2013 Solta Medical, Inc. 25881 Industrial Blvd. Hayward, CA 94545 Attention: Vice President, Finance Re: Lock-up Agreement Ladies and Gentlemen: Sound Surgical Technologies LLC, a Colorado limited liability company ("Company"), is a party to an Agreement and Plan of Merger dated January 29, 2013 (the "Merger Agreement"), by and among Solta Med |
|
| April 11, 2013 |
Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2013 |
DEL AM Solta Medical, Inc. 25881 Industrial Boulevard Hayward, California 64545 April 5, 2013 VIA EDGAR AND OVERNIGHT DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Solta Medical, Inc. Registration Statement on Form S-3 Filed April 1, 2013 Registration No. 333-187657 Ladies and Gentlemen: Pursuant to Rule 473( |
|
| April 1, 2013 |
S-3 1 d513868ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on April 1, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 68-0373593 (State or other jurisdiction of inc |
|
| March 21, 2013 |
NINTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.1 NINTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS NINTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 18, 2013 by and between SILICON VALLEY BANK (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into that certain Lo |
|
| March 21, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commiss |
|
| March 6, 2013 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 6, 2013 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF SOLTA MEDICAL, INC. A DELAWARE CORPORATION Subsidiaries Jurisdiction Reliant Technologies, LLC Delaware Solta Medical International, Inc. Delaware Reliant Medical Lasers, Inc. California Reliant Medical Lasers, LLC California Aesthera Corporation California CLRS Technology Corporation California Liposonix, Inc. California Solta Medical Kabushiki Kaisha Japan So |
|
| February 26, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 26, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| February 26, 2013 |
Exhibit 99.1 NEWS RELEASE MEDIA RELATIONS: JENNIFER HACKER COHN & WOLFE (404) 260-3509 [email protected] INVESTOR RELATIONS: DOUG SHERK/JENIFER KIRTLAND (415) 568-9349 SOLTA MEDICAL COMPLETES ACQUISITION OF SOUND SURGICAL TECHNOLOGIES HAYWARD, Calif., February 26, 2013—Solta Medical, Inc. (Solta) (NASDAQ:SLTM) today announced the completion of its acquisition of privately-held Sound Su |
|
| February 26, 2013 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER This Agreement and Plan of Merger (this “Agreement”) is entered into as of January 29, 2013, by and among Sound Surgical Technologies LLC, a Colorado limited liability company (the “Company”), Solta Medical, Inc., a Delaware corporation (“Parent”), Argonaut Limited Liability Company, a Colorado limited liability company and wholly |
|
| February 19, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d488551d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2013 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of |
|
| February 19, 2013 |
EX-99.1 2 d488551dex991.htm EX-99.1 Exhibit 99.1 Solta Medical Reports Fourth Quarter and Full Year 2012 Results Fourth Quarter Revenue Up 20% from Prior Year; 2012 Revenue up 25% Approximately 360 Liposonix Systems Shipped in 2012; $32 Million in Revenue Company Provides Financial Outlook for 2013 HAYWARD, Calif., February 19, 2013 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medi |
|
| February 13, 2013 |
SLTM / Solta Medical Inc / MERITECH CAPITAL PARTNERS II LP - FORM SC 13GA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3) * Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2012 (Date of Event Which Require |
|
| February 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 4, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| January 29, 2013 |
Press Release Exhibit 99.1 Solta Medical to Acquire Sound Surgical Technologies Transaction Expands Solta’s Presence in the Body Contouring Market and is Expected to be Accretive within 12 Months Solta Provides Preliminary Fourth Quarter 2012 Results Conference Call Today at 6 p.m. EST HAYWARD, Calif., January 29, 2013 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics |
|
| January 29, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 29, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| January 28, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 27, 2013 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| November 1, 2012 |
Press Release Exhibit 99.1 Solta Medical Reports Third Quarter Results Third Quarter Revenue Up 28% from Prior Year Liposonix, Thermage, Fraxel, and Clear + Brilliant All Generate Revenue Growth HAYWARD, Calif., November 1, 2012 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2012. Revenue for |
|
| November 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 S |
|
| September 4, 2012 |
Loan and Security Agreement Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 29, 2012 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agr |
|
| September 4, 2012 |
EIGHTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.2 EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS EIGHTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of August 29, 2012 by and between SILICON VALLEY BANK (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into that certain |
|
| September 4, 2012 |
8-K 1 d406105d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 29, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of inc |
|
| August 27, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 21, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| August 27, 2012 |
AMENDMENT TO STOCK PURCHASE AGREEMENT Amendment to Stock Purchase Agreement Exhibit 10.1 AMENDMENT TO STOCK PURCHASE AGREEMENT THIS AMENDMENT to Stock Purchase Agreement, dated as of August 21, 2012 (this “Amendment”), is entered into by and between Solta Medical, Inc., a Delaware corporation (“Buyer”), and Medicis Pharmaceutical Corporation, a Delaware corporation (“Seller”), and amends that certain Stock Purchase Agreement, dated as |
|
| August 14, 2012 |
SLTM / Solta Medical Inc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 Amendment No. 1 to Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 2, 2012 |
Exhibit 1.1 SOLTA MEDICAL, INC. 5,700,000 Shares of Common Stock (Plus an Option to Purchase up to 855,000 Shares to Cover Over-allotments) UNDERWRITING AGREEMENT August 2, 2012 CANACCORD GENUITY INC. As Representative of the several Underwriters named in Schedule III hereto c/o Canaccord Genuity Inc. 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Solta Medical, Inc., |
|
| August 2, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2012 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| August 2, 2012 |
5,700,000 Shares Solta Medical, Inc. Common Stock 424B2 1 d387471d424b2.htm FILED PURSUANT TO RULE 424(B)(2) Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-181074 PROSPECTUS SUPPLEMENT (To prospectus dated May 1, 2012) 5,700,000 Shares Solta Medical, Inc. Common Stock We are offering 5,700,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the trading symbol “SLTM.” On August 1, 2 |
|
| August 2, 2012 |
Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock Press Release Exhibit 99.1 Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock HAYWARD, Calif., August 2, 2012 — Solta Medical, Inc. (NASDAQ: SLTM) today announced that it has priced its previously announced underwritten public offering of 5,700,000 shares of its common stock at a purchase price of $2.65 per share. Net proceeds, after underwriting discounts and estimated offerin |
|
| August 1, 2012 |
SUBJECT TO COMPLETION, DATED AUGUST 1, 2012 424B3 1 d387471d424b3.htm FILED PURSUANT TO RULE 424(B)(3) Table of Contents This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but are not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not solici |
|
| August 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 SOLTA MEDICAL, |
|
| July 26, 2012 |
Press Release Exhibit 99.1 Solta Medical Reports Second Quarter Results Second Quarter Revenue Up 29% from Prior Year Production of Liposonix® Systems Up 40% from Q1 2012 to Meet Growing Demand Company Generates $4.0 Million in Cash Flow from Operations HAYWARD, Calif., July 26, 2012 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for |
|
| July 26, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 26, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commissi |
|
| June 8, 2012 |
Submission of Matters to a Vote of Security Holders 8-K 1 d364608d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2012 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorp |
|
| May 30, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 1, 2012 |
Press Release Exhibit 99.1 Solta Medical Reports First Quarter Results First Quarter Revenue Up 23% from Prior Year Launch of Liposonix Exceeds Expectations HAYWARD, Calif., May 1, 2012 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2012. Revenue for the first quarter was $32.5 million, an increa |
|
| May 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2012 |
Form of Debt Security EXHIBIT 4.5 FORM OF DEBT SECURITY [Face of Security] SOLTA MEDICAL, INC. [If applicable, insert – FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOU |
|
| May 1, 2012 |
S-3 1 d281808ds3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on May 1, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 68-0373593 (State or other jurisdiction o |
|
| May 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 SOLTA |
|
| May 1, 2012 |
Statement of Computation of Ratio of Earnings to Fixed Charges Exhibit 12.1 Statement of Calculation of Ratio of Earnings (Loss) to Fixed Charges (in thousands, except ratios) Fiscal Year ended December 31, Fiscal Quarter Ended 2007 2008 2009 2010 2011 March 31, 2012 Calculation of Earnings Income (loss) before income taxes $ 3,051 $ (16,379 ) $ (11,291 ) $ (1,798 ) $ (7,489 ) $ (8,742 ) Fixed cha |
|
| May 1, 2012 |
Exhibit 4.6 SOLTA MEDICAL, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 6 2.3. EXECUTION |
|
| April 23, 2012 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2012 |
Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2012 |
Table of Contents Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SOLTA MEDICAL, INC. (effective as of November 15, 2006, as amended and restated on April 10, 2012) Table of Contents TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTI |
|
| April 12, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2012 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| March 28, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2012 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| March 14, 2012 |
LANDLORD?S CONSENT TO ASSIGNMENT OF LEASE IN CONNECTION WITH ACQUISITION Exhibit 10.30 LANDLORD?S CONSENT TO ASSIGNMENT OF LEASE IN CONNECTION WITH ACQUISITION This Landlord?s Consent to Assignment of Lease in Connection with Acquisition (this ?Agreement?), effective as of the 28th day of October, 2011, by and between S/I NORTH CREEK I, LLC, a Washington limited liability company (?Landlord?), and MEDICIS TECHNOLOGIES CORPORATION (f/k/a LipoSonix, Inc.), a Delaware cor |
|
| March 14, 2012 |
Exhibit 10.29 SCHNITZER NORTH CREEK, BUSINESS CENTER LEASE AGREEMENT S/I NORTH CREEK I, LLC (Landlord) and LIPOSONIX, INC. (Tenant) Dated: May 30th, 2007 TABLE OF CONTENTS ARTICLE I: DEFINITIONS 1 1.01 Defined terms 1 ARTICLE II: PREMISES AND COMMON AREAS LEASED 3 2.01 Premises 3 2.02 Common Areas 4 ARTICLE III: IMPROVEMENTS 6 3.01 Construction of Building and Premises 6 3.02 Completion and Delive |
|
| March 14, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2011 Commission File Number: 001-33123 SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 68-0373593 (State or other jurisdiction of incorporation |
|
| March 14, 2012 |
Exhibit 10.31 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is dated for reference purposes as of the 27th day of January, 2012, by and among S/I NORTH CREEK I, LLC, a Washington limited liability company (“Landlord”), LIPOSONIX, INC. (f/k/a Medicis Technologies Corporation), a Delaware corporation (“Tenant”), and SOLTA MEDICAL, INC., a Delaware corporation (“Guarantor” |
|
| March 14, 2012 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF SOLTA MEDICAL, INC. A DELAWARE CORPORATION Subsidiaries Jurisdiction Reliant Technologies, LLC Delaware Solta Medical International, Inc. Delaware Reliant Medical Lasers, Inc. California Reliant Medical Lasers, LLC California Aesthera Corporation California CLRS Technology Corporation California Liposonix, Inc. California Reliant Technologies Kabushiki Kaisha J |
|
| March 14, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on March 14, 2012 Registration No. |
|
| February 14, 2012 |
SLTM / Solta Medical Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Solta Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 13, 2012 |
Press Release Exhibit 99.1 Solta Medical Reports Fourth Quarter 2011 Results Fourth Quarter Product Revenue Up 11% from Prior Year Ninth Consecutive Quarter of Non-GAAP Operating Income Company Commences Shipments of Liposonix Systems HAYWARD, Calif., February 13, 2012 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today reported product revenue during the |
|
| February 13, 2012 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 13, 2012 |
SLTM / Solta Medical Inc / MERITECH CAPITAL PARTNERS II LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2) * Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2011 (Date of Event Which Require |
|
| January 17, 2012 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 9, 2012 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| January 17, 2012 |
Press Release Exhibit 99.1 Solta Medical Affirms Q4 2011 Financial Outlook Company to Meet with Investors at Needham and JP Morgan Conferences HAYWARD, Calif., January 9, 2011- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today reiterated the company’s expectations for its financial results for the fourth quarter ended December 31, 2011 as follows: • The co |
|
| January 11, 2012 |
Exhibit 99.1 CONSOLIDATED FINANCIAL STATEMENTS Medicis Technologies Corporation For the Nine Months Ended September 30, 2011 (unaudited), the Nine Months Ended September 30, 2010 (unaudited) and the Years Ended December 31, 2010 and 2009 With Report of Independent Auditors Medicis Technologies Corporation Consolidated Financial Statements For the Nine Months Ended September 30, 2011 (unaudited), t |
|
| January 11, 2012 |
Form 8-K Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 1, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| January 11, 2012 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANICAL STATEMENTS EX-99.2 4 d281249dex992.htm UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANICAL STATEMENTS Introductory Note to Unaudited Pro Forma Condensed Combined Financial Statements On September 12, 2011, Solta Medical, Inc. (“Solta or the Company”) entered into a stock purchase agreement (“Purchase Agreement”) with Medicis Pharmaceutical Corporat |
|
| December 23, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Comm |
|
| November 18, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 17, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Comm |
|
| November 3, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2011 |
SIXTH AMENDMENT LOAN AND SECURITY AGREEMENT Sixth Amendment to Loan and Security Agreement Exhibit 10.1 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 12th day of September, 2011 by and between SILICON VALLEY BANK (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECI |
|
| November 2, 2011 |
SOLTA AND MEDICIS ANNOUNCE CLOSE OF AGREEMENT FOR LIPOSONIX? Exhibit 99.1 CONTACT: Solta Medicis Lindsay Caulfield (media) Kara Stancell (media) (404) 200-0709 (480) 291-5454 Jenifer Kirtland (investors) Sean Andrews (investors) (415) 568-9349 (480) 291-5854 SOLTA AND MEDICIS ANNOUNCE CLOSE OF AGREEMENT FOR LIPOSONIX? HAYWARD, Calif. and SCOTTSDALE, Ariz.?November 1, 2011? Solta Medical, Inc. (Solta) (NASDAQ:SLTM) and Medicis Pharmaceutical Corporation (Med |
|
| November 2, 2011 |
Stock Purchase Agreement Exhibit 10.2 Execution Version STOCK PURCHASE AGREEMENT by and between MEDICIS PHARMACEUTICAL CORPORATION (“Seller”) and SOLTA MEDICAL, INC. (“Buyer”) dated as of September 12, 2011 Table of Contents Page ARTICLE 1 DEFINITIONS AND REFERENCES 2 ARTICLE 2 PURCHASE AND SALE OF THE SHARES; PURCHASE PRICE 2 Section 2.1 Purchase and Sale of the Shares. 2 Section 2.2 Purchase Pri |
|
| November 2, 2011 |
SEVENTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.3 SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SEVENTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 25th day of October, 2011 by and between SILICON VALLEY BANK (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into t |
|
| November 2, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 1, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| November 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 S |
|
| November 1, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commi |
|
| November 1, 2011 |
Exhibit 99.1 Solta Medical Reports Third Quarter Results Product Revenue Up 14% from Prior Year Sales of New Systems and Upgrades Up 19% Eighth Consecutive Quarter of Non-GAAP Operating Income Second Generation LipoSonix? System Receives CE Mark, Worldwide Launch Planned for Q1 2012 HAYWARD, Calif., November 1, 2011 ? Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics ma |
|
| October 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 25, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 28, 2011 |
Exhibit 99.1 Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility with Silicon Valley Bank to $28 Million HAYWARD, Calif., October 26, 2011 – Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it has signed an amendment with Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), under which the company’s cre |
|
| October 27, 2011 |
Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix? System Exhibit 99.1 Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix? System HAYWARD, Calif., October 24, 2011 ? Solta Medical, Inc. (Solta) (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced that Medicis Technologies Corporation (formerly LipoSonix, Inc.), a subsidiary of Medicis Phamaceutical Corporation (Medicis) has received U.S. Food and Dru |
|
| October 27, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 24, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| October 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Solta Medical, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 83438k103 (CUSIP Number) October 3, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| October 5, 2011 |
Pending Acquisition of LipoSonix Pending Acquisition of LipoSonix October 5, 2011 Exhibit 99.1 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include, but are not limited to, anticipated timing of U.S. Food and Drug Administration and European Union clearance of the secon |
|
| October 5, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 5, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| September 15, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 12, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. |
|
| September 15, 2011 |
MEDICIS AND SOLTA ANNOUNCE AGREEMENT FOR LIPOSONIX® Press Release Exhibit 99.1 CONTACT: Medicis Solta Kara Stancell (media) Lindsay Caulfield (media) (480) 291-5454 (404) 200-0709 Sean Andrews (investors) Jenifer Kirtland (investors) (480) 291-5854 (415) 568-9349 MEDICIS AND SOLTA ANNOUNCE AGREEMENT FOR LIPOSONIX® SCOTTSDALE, Ariz. and HAYWARD, Calif.—September 13, 2011—Medicis Pharmaceutical Corporation (Medicis) (NYSE:MRX) and Solta Medical, Inc. |
|
| August 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil |
|
| August 2, 2011 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 2, 2011 |
Exhibit 99.1 Solta Medical Reports Second Quarter Results Revenue from Treatment Tips and Other Consumables Up 10% from Prior Year Seventh Consecutive Quarter of Non-GAAP Operating Income HAYWARD, Calif., August 2, 2011 ? Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the second quarter ended June 30, 2011. Second quarter 2011 reve |
|
| July 29, 2011 |
Form 8-K Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2011 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| July 14, 2011 |
Response Letter July 14, 2011 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Attention: Kevin L. Vaughn Martin James Lynn A. Dicker Re: Solta Medical, Inc. Form 10-K for Fiscal Year Ended December 31, 2010 Filed March 16, 2011 File No. 1-33123 Ladies and Gentlemen: Solta Medical, Inc. (the “Company”) provides this re |
|
| June 17, 2011 |
June 17, 2011 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Attention: Kevin L. Vaughn Martin James Re: Solta Medical, Inc. Form 10-K for Fiscal Year Ended December 31, 2010 Filed March 16, 2011 File No. 1-33123 Ladies and Gentlemen: Solta Medical, Inc. (the “Company”) provides this response to the comments of the s |
|
| June 8, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2011 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| June 6, 2011 |
rrd281752318524.html EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. (the "Company"), hereby constitutes and appoints Stephen J. Fanning and John F. Glenn, and each of them, the undersigned's true and lawful attorney in fact and agent to complete and execute such Forms 144, Forms 3, 4 and 5 and other forms as such attorney |
|
| May 4, 2011 |
Exhibit 10.3 SOLTA MEDICAL, INC. 2006 EQUITY INCENTIVE PLAN (As Amended and Restated April 13, 2010 and Amended on April 6, 2011) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Compa |
|
| May 4, 2011 |
Form of Notice of Grant for, and Terms and Conditions of, Market Stock Units Exhibit 10. |
|
| May 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report on Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 3, 2011 |
Press Release Exhibit 99.1 Solta Medical Reports First Quarter Results Revenue from Treatment Tips and Other Consumables Up 18% from Prior Year HAYWARD, Calif., May 3, 2011 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2011. Revenue for the first quarter was $26.5 million, a 2% increase as compa |
|
| May 3, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2011 |
FIFTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into this 20th day of April, 2011 by and between SILICON VALLEY BANK (?Bank?) and SOLTA MEDICAL, INC., a Delaware corporation (?Borrower?) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into that ce |
|
| April 25, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 20, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commiss |
|
| April 22, 2011 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2010 Commission File Number: 001-33123 SOLTA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 68-0373593 (State or other jurisdiction of incorporation |
|
| April 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 6, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 23, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2011 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| March 16, 2011 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF SOLTA MEDICAL, INC. A DELAWARE CORPORATION Subsidiaries Jurisdiction Reliant Technologies, LLC Delaware Solta Medical International, Inc. Delaware Reliant Medical Lasers, Inc. California Reliant Medical Lasers, LLC California Aesthera Corporation California CLRS Technology Corporation California Reliant Technologies Kabushiki Kaisha Japan Aesthera Corporation K |
|
| March 16, 2011 |
As filed with the Securities and Exchange Commission on March 16, 2011 As filed with the Securities and Exchange Commission on March 16, 2011 Registration No. |
|
| March 16, 2011 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 16, 2011 |
FOURTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.29 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into this 15th day of October, 2010 by and between SILICON VALLEY BANK (?Bank?) and SOLTA MEDICAL, INC., a Delaware corporation (?Borrower?) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS A. Bank and Borrower have entered into th |
|
| March 1, 2011 |
rrd271978307277.html EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. (the "Company"), hereby constitutes and appoints Stephen J. Fanning and John F. Glenn, and each of them, the undersigned's true and lawful attorney in fact and agent to complete and execute such Forms 144, Forms 3, 4 and 5 and other forms as such attorney |
|
| February 22, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2011 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Comm |
|
| February 22, 2011 |
Exhibit 99.1 Solta Medical Reports Fourth Quarter and Full Year 2010 Results Full Year 2010 Revenue Up 12% from Prior Year Company Generates Record $10.2 Million in Cash Flow from Operations for 2010 Preliminary Outlook for 2011 Provided HAYWARD, Calif., February 22, 2011 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the fourth |
|
| February 16, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2011 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| February 15, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2010 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2011 |
EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. |
|
| February 14, 2011 |
rrd269865304984.html EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. (the "Company"), hereby constitutes and appoints Stephen J. Fanning and John F. Glenn, and each of them, the undersigned's true and lawful attorney in fact and agent to complete and execute such Forms 144, Forms 3, 4 and 5 and other forms as such attorney |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A OMB APPROVAL Under the Securities Exchange Act of 1934 OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4 (Amendment No. 1)* Solta Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2010 (Date of Event wh |
|
| February 11, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) * Solta Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83438K103 (CUSIP Number) December 31, 2010 (Date of Event Which Require |
|
| November 3, 2010 |
Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED AS [REDACTED] TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO NON-COMPETITION AND NON-SOLICITATION AGREEMENT |
|
| November 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 S |
|
| November 2, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2010 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2010 |
Press Release Exhibit 99.1 Solta Medical Reports Third Quarter 2010 Results Revenue from Treatment Tips and Other Consumables Up 40% from Prior Year HAYWARD, Calif., November 2, 2010 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2010. Revenue for the third quarter was $24.9 million, an incre |
|
| October 21, 2010 |
FOURTH AMENDMENT LOAN AND SECURITY AGREEMENT Fourth Amendment to the Loan and Security Agreement - Silicon Valley Bank Exhibit 10. |
|
| October 21, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 15, 2010 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2010 |
Press Release Exhibit 99.1 NEWS RELEASE 25881 INDUSTRIAL BLVD., HAYWARD, CA 94545 MAIN 510-782-2286 FAX 510-782-2287 WWW.SOLTA.COM SOLTA MEDICAL TO ACQUIRE CLRS TECHNOLOGY Company Becomes an Early-Entrant in the Personal Care Aesthetics Market HAYWARD, Calif., October 18, 2010 – Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced it has acquired pr |
|
| October 1, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 29, 2010 Date of Report (Date of earliest event reported) SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33123 68-0373593 (State or other jurisdiction of incorporation) (Com |
|
| September 16, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 15, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| August 13, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| August 4, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 3, 2010 |
Exhibit 99.1 Solta Medical Reports Second Quarter 2010 Results Revenue of $30.1 million up $2.7 million or 10% from Q2 2009 Company Generates Record $7.7 million in Cash Flow from Operations HAYWARD, Calif., August 3, 2010 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the second quarter ended June 30, 2010. The results for the q |
|
| August 3, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| June 8, 2010 |
SOLTA MEDICAL, INC. 2006 EQUITY INCENTIVE PLAN (As Amended and Restated April 13, 2010) Exhibit 10.1 SOLTA MEDICAL, INC. 2006 EQUITY INCENTIVE PLAN (As Amended and Restated April 13, 2010) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permi |
|
| June 8, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| June 7, 2010 |
EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. |
|
| June 7, 2010 |
EXHIBIT 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Thermage, Inc. |
|
| May 14, 2010 |
2,435,897 Shares Solta Medical, Inc. Common Stock Filed Pursuant to Rule 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| May 12, 2010 |
Solta Medical, Inc. 25881 Industrial Boulevard Hayward, CA 94545 May 11, 2010 Acceleration Request Solta Medical, Inc. 25881 Industrial Boulevard Hayward, CA 94545 May 11, 2010 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Facsimile: (202) 772-9349 Attention: Russell Mancuso Mary Beth Breslin Re: Solta Medical, Inc.–Request for Acceleration of Effectiveness of the Registrati |
|
| May 11, 2010 |
Solta Medical, Inc. 25881 Industrial Boulevard Hayward, CA 94545 May 11, 2010 Acceleration Request Solta Medical, Inc. 25881 Industrial Boulevard Hayward, CA 94545 May 11, 2010 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Facsimile: (202) 772-9349 Attention: Russell Mancuso Mary Beth Breslin Re: Solta Medical, Inc.–Request for Acceleration of Effectiveness of the Registrati |
|
| May 11, 2010 |
As filed with the Securities and Exchange Commission on May 11, 2010 Amendment No. 2 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on May 11, 2010 Registration No. 333-165618 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 68-0373593 (State |
|
| May 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33123 SOLTA |
|
| May 4, 2010 |
Press Release Exhibit 99.1 Solta Medical Reports First Quarter 2010 Results Treatment Tip and Consumables Revenue Rise by $1.9 Million or 15% from Q4 2009 Conference Call Today at 4:30 p.m. ET HAYWARD, Calif., May 4, 2010 — Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2010. Revenue for the first |
|
| May 4, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| April 28, 2010 |
Lock-Up Agreement (Pinnacle) Exhibit 4.6 LOCK-UP AGREEMENT This Lock-Up Agreement (this “Agreement”) is dated as of February 22, 2010, by and between Solta Medical, Inc., a Delaware corporation (“Parent”), and the undersigned Stockholder (the “Stockholder”) of Aesthera Corporation, a Delaware corporation (the “Company”). Capitalized terms used herein but not defined herein shall have the meanings |
|
| April 28, 2010 |
As filed with the Securities and Exchange Commission on April 28, 2010 S-3/A 1 ds3a.htm AMENDMENT NO. 1 TO FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2010 Registration No. 333-165618 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 SOLTA MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delawar |
|
| April 23, 2010 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2010 |
April 8, 2010 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Attention: Russell Mancuso Mary Beth Breslin Kevin Vaughn Re: Solta Medical, Inc. Registration Statement on Form S-3 Filed March 22, 2010 File No. 333-165618 Ladies and Gentlemen: Solta Medical, Inc. (the ?Company?) provides this response to the comments of |
|
| April 5, 2010 |
Solta Medical Expands Credit Facility with Silicon Valley Bank to $22 Million Press Release Exhibit 99.1 News Solta Medical Expands Credit Facility with Silicon Valley Bank to $22 Million Santa Clara, Calif. –– March 31, 2010 — Silicon Valley Bank (NASDAQ: SIVB), financial partner to technology companies of all sizes worldwide, added a new $10 million term loan to existing credit facilities for Solta Medical (NASDAQ: SLTM), a global leader in the medical aesthetics market. |
|
| April 5, 2010 |
THIRD AMENDMENT LOAN AND SECURITY AGREEMENT Third Amendment to Loan and Security Agreement Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 31st day of March, 2010 by and between Silicon Valley Bank (“Bank”) and SOLTA MEDICAL, INC., a Delaware corporation (“Borrower”) whose address is 25881 Industrial Boulevard, Hayward, CA 94545. RECITALS |
|
| April 5, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2010 Date of Report (date of earliest event reported) SOLTA MEDICAL, INC. |
|
| March 23, 2010 |
As filed with the Securities and Exchange Commission on March 22, 2010 As filed with the Securities and Exchange Commission on March 22, 2010 Registration No. |
|
| March 22, 2010 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 22, 2010 |
Agreement and Plan of Merger Exhibit 2.1 CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG SOLTA MEDICAL, INC. APOLLO ATC MERGER CORP., AESTHERA CORPORATION, AND DANA MEAD, AS HOLDER REPRESENTATIVE Dated as of February 22, 2010 CONFIDENTIAL TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Additional Defined Terms 9 1.3 Interpretations 12 ARTICLE II THE MERGER 13 |
|
| March 22, 2010 |
Exhibit 4.5 SOLTA MEDICAL, INC. REGISTRATION RIGHTS AGREEMENT Dated as of February 22, 2010 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1. Definitions 1 Section 1.2. General Interpretive Principles 2 ARTICLE II REGISTRATION RIGHTS Section 2.1. Certain Definitions 3 Section 2.2. Shelf Registration 3 Section 2.3. Expenses of Registration 6 Section 2.4. Obligations of the Company 7 Section |
|
| March 22, 2010 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF SOLTA MEDICAL, INC. A DELAWARE CORPORATION Subsidiaries Jurisdiction Reliant Technologies, LLC Delaware Solta Medical International, Inc. Delaware Reliant Technologies Kabushiki Kaisha Japan Reliant Medical Lasers, Inc. California |
|
| March 22, 2010 |
As filed with the Securities and Exchange Commission on March 22, 2010 Table of Contents As filed with the Securities and Exchange Commission on March 22, 2010 Registration No. |
|
| March 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Solta Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 88343R 10 1 (CUSIP Number) March 15, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| March 15, 2010 |
Exhibit 99.1 Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Solta Medical, Inc. Dated: March 15, 2010 INSTITUTIONAL VENTURE PARTNER |
